Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome

NCT01813630 is registered in ClinicalTrials.gov with Dong-A ST Co., Ltd. as lead sponsor.

NCT NCT01813630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01813630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome
Lead sponsor
Dong-A ST Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2013
Completion date
May 31, 2018
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

turner's syndrome